Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
Publication/Presentation Date
11-2023
Volume
11
Published In/Presented At
Spigel DR, Hamilton E, Bashir B, Gergis U, Murthy HS, Chumsri S, et al. 754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). Journal for ImmunoTherapy of Cancer. 2023;11:. https://doi.org/10.1136/jitc-2023-SITC2023.0754
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS